{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:24:43Z","timestamp":1767597883387,"version":"3.37.3"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00277-022-05031-2","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T06:05:06Z","timestamp":1669615506000},"page":"237-238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Platelet recovery with ibrutinib therapy in patient with treatment-refractory immune thrombocytopenia"],"prefix":"10.1007","volume":"102","author":[{"given":"Paul Christopher","family":"Parish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald C.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0901-4866","authenticated-orcid":false,"given":"Justin","family":"Arnall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa J.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"Dick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Cambareri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"issue":"22","key":"5031_CR1","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","volume":"3","author":"D Provan","year":"2019","unstructured":"Provan D, Arnold DM, Bussel JB et al (2019) Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 3(22):3780\u20133817","journal-title":"Blood Adv"},{"issue":"4","key":"5031_CR2","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1182\/blood-2003-11-3908","volume":"104","author":"R McMillan","year":"2004","unstructured":"McMillan R, Durette C (2004) Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 104(4):956\u2013960","journal-title":"Blood"},{"key":"5031_CR3","doi-asserted-by":"publisher","first-page":"662223","DOI":"10.3389\/fimmu.2021.662223","volume":"12","author":"GE Ringheim","year":"2021","unstructured":"Ringheim GE, Wampole M, Oberoi K (2021) Bruton\u2019s Tyrosine Kinase (BTK) Inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures. Front Immunol 12:662223","journal-title":"Front Immunol"},{"issue":"2","key":"5031_CR4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/leu.2015.273","volume":"30","author":"KA Rogers","year":"2016","unstructured":"Rogers KA, Ruppert AS, Bingman A et al (2016) Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia 30(2):346\u2013350","journal-title":"Leukemia"},{"issue":"5","key":"5031_CR5","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/jth.13651","volume":"15","author":"JJ Shatzel","year":"2017","unstructured":"Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, DeLoughery TG (2017) Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost 15(5):835\u2013847","journal-title":"J Thromb Haemost"},{"key":"5031_CR6","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","volume":"386","author":"DJ Kuter","year":"2022","unstructured":"Kuter DJ, Efraim M, Mayer J et al (2022) Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia. N Engl J Med 386:1421\u20131431","journal-title":"N Engl J Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05031-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-05031-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05031-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T03:05:00Z","timestamp":1672715100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-05031-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["5031"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-05031-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2022,11,28]]},"assertion":[{"value":"4 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A \u2014 This is a case report of therapy selection and response to therapy outside of a clinical trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Institutional review board reviewed, and patient consent identified was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Conflicts of interest are listed below for each author. In brief, authors with conflicts of interest are Donald Moore and Justin Arnall. No identified conflicts of interest played a role in therapy selection or report of this patient case.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}